@article{dda2a856e097478eb9941d923f06455d,
title = "Tesaglitazar, a novel dual peroxisome proliferator-activated receptor α/γ agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population",
keywords = "Cardiovascular risk factors, Dyslipidaemia, HDL-cholesterol, Hyperinsulinaemia, Hypoglycaemic agents, Insulin resistance, LDL-cholesterol, Peroxisome proliferator-activated receptor, Triglycerides, Humans, Middle Aged, Insulin/blood, Fatty Acids, Nonesterified/blood, Male, Dose-Response Relationship, Drug, PPAR gamma/antagonists \& inhibitors, Phenylpropionates/adverse effects, Placebos, Female, Safety, Double-Blind Method, Alkanesulfonates/adverse effects, Blood Glucose/drug effects, Triglycerides/blood, PPAR alpha/antagonists \& inhibitors, Lipids/blood",
author = "B. Fagerberg and S. Edwards and T. Halmos and J. Lopatynski and H. Schuster and S. Stender and G. Stoa-Birketvedt and S. Tonstad and S. Halld{\'o}rsd{\'o}ttir and I. Gause-Nilsson",
note = "Funding Information: Acknowledgements The authors would like to thank Dr Peter {\"O}hman and all the investigators for their valuable contribution to the study. The authors also acknowledge the AstraZeneca publication team for editorial assistance. Duality of interest: B. Fagerberg and S. Edwards have received grants from Astra-Zeneca; H. Schuster has received an honorarium and grant from AstraZeneca; S. Tonstad has received grants and lecture/other fees from AstraZeneca; and S. Halld{\'o}rsd{\'o}ttir and I. Gause-Nilsson are employed by AstraZeneca.",
year = "2005",
month = sep,
doi = "10.1007/s00125-005-1846-8",
language = "English",
volume = "48",
pages = "1716--1725",
journal = "Diabetologia",
issn = "0012-186X",
number = "9",
}